蛋白尿变化与免疫复合物型MPGN及C3肾小球病的纵向结局比较
该多中心回顾性纵向研究纳入149例患者(C3G 98例,IC-MPGN 51例),中位随访65个月,44例(30%)进展至肾衰竭。蛋白尿纵向增加与肾衰竭风险强相关,蛋白尿较基线下降≥50%与肾衰竭风险降低相关(HR 0.61,95%CI 0.46-0.75,P<0.001),且在C3G和IC-MPGN中一致。
要点
- 蛋白尿较基线下降≥50%与肾衰竭风险降低独立相关(HR 0.61)。
- 6个月蛋白尿下降≥30%或12个月下降≥50%与eGFR下降更慢相关。
- 时间平均蛋白尿<1 g/d提示肾脏结局更好。
核心结论
- 在C3G和IC-MPGN中,蛋白尿下降与更好的肾脏结局及更慢的eGFR下降相关。
研究设计与样本
- 多中心回顾性纵向研究,纳入149例患者(C3G 98例,IC-MPGN 51例),中位年龄35岁,中位随访65个月。
- 采用联合线性混合效应模型评估蛋白尿轨迹,Cox回归评估其与肾衰竭的关联,并计算时间平均蛋白尿(TA-P)。
主要发现
- 随访期间44例(30%)进展至肾衰竭,C3G与IC-MPGN之间无差异。
- 蛋白尿纵向增加与肾衰竭风险强相关;蛋白尿较基线下降≥50%与肾衰竭风险降低相关(HR 0.61,95%CI 0.46-0.75,P<0.001)。
- 上述关联在C3G和IC-MPGN中一致,在基线eGFR≥30 ml/min/1.73 m2且蛋白尿≥1 g/d的患者中也一致。
- 6个月蛋白尿下降≥30%或12个月下降≥50%与eGFR下降更慢相关。
- 按TA-P水平分为4个亚组,TA-P<1 g/d提示肾脏结局更好。
临床怎么用
- 在C3G和IC-MPGN患者中,动态监测蛋白尿变化可作为肾脏预后评估的重要指标。
- 治疗目标可考虑实现蛋白尿较基线下降≥50%,尤其对于基线eGFR≥30 ml/min/1.73 m2且蛋白尿≥1 g/d的患者。
- 时间平均蛋白尿<1 g/d可能提示更好的肾脏结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: C3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) are rare diseases that share a similar pathogenesis; however, the prognostic significance of proteinuria reduction remains poorly characterized. This study compared the outcomes in C3G and IC-MPGN and assessed the impact of changes in proteinuria on kidney prognosis. METHODS: This retrospective, longitudinal, multicenter study used joint linear mixed-effects models to assess proteinuria trajectories, and Cox regression to evaluate their association with kidney failure. In addition, time-averaged proteinuria (TA-P) was calculated to determine its impact on kidney prognosis. RESULTS: The study included 149 patients: 98 with C3G (66%) and 51 with IC-MPGN (34%) with a median age of 35 (interquartile range [IQR]: 22-53) years. During a median follow-up of 65 (IQR: 32-114) months, 44 patients (30%) progressed to kidney failure without differences across C3G or IC-MPGN. A strong association was observed between longitudinal increase in proteinuria and the risk of kidney failure. In addition, a ≥ 50% proteinuria reduction over time was associated with a lower risk of kidney failure (hazard ratio [HR]: 0.61; 95% confidence interval [CI]: 0.46-0.75, P < 0.001). Results were consistent in both C3G and IC-MPGN, and in those with baseline estimated glomerular filtration rate (eGFR) ≥ 30 ml/min per 1.73 m2 and proteinuria ≥ 1 g/d. A ≥30% proteinuria reduction at 6 months or a ≥50% proteinuria reduction at 12 months were associated with a slower eGFR decline. Patients were categorized into 4 subgroups based on TA-P levels, with TA-P values < 1 g/d indicating better kidney outcomes. CONCLUSION: Proteinuria reduction was associated with improved kidney outcomes and slower eGFR decline in both C3G and IC-MPGN.
引用
- Caravaca-Fontán F, Toledo-Rojas R, Huerta A, et al. Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy. Kidney Int Rep. 2025. PMID: 40303231. doi:10.1016/j.ekir.2025.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。